Efficacy of Albumin Plus Midodrine v/s Albumin Alone in Reducing Incidence of Paracentesis Induced Circulatory Dysfunctions in ACLF Patients.

• Status: Not yet recruiting
• Trial end date: 2021-03-31
• Target enrollment: 0
• Participant gender: All

Summary

The patients with ACLF having Ascites who require ascitic tapping will undergone ascitic tapeither under albumin cover alone or with midodrine. The patient will be monitored for complication and changes of PICD. Study analysis will be done with primary objective being reduction in incidence of PICD.

• Phase: N/A
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Institute of Liver and Biliary Sciences, India
• Treatments: Midodrine

Criteria

Inclusion Criteria:

• ACLF patients (as per APASL definition) with grade II/III ascites

Exclusion Criteria:

1. Age < 18 or >75 years

2. Hepatocellular carcinoma

3. Extrahepatic portal vein obstruction

4. Non cirrhotic ascites

5. Serum creatinine >1.5mg/dl

6. Refractory septic shock

7. Beta blockersPortal vein thrombosis

8. Grade 3-4 HE

9. Pregnancy or Lactation

10. Active variceal bleed

11. Respiratory, cardiac, renal failure

12. Uncontrolled hypertension

13. Severe coagulopathy

14. Refusal to participate